(6-Nitro-1,1,3-trioxo-1,3-dihydro-1λ⁶-benzo[d]isothiazol-2-yl)-acetic acid ethyl ester | 178755-48-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (6-Nitro-1,1,3-trioxo-1,3-dihydro-1λ⁶-benzo[d]isothiazol-2-yl)-acetic acid ethyl ester
• 英文别名: Ethyl 2-(6-nitro-1,1,3-trioxo-1,2-benzothiazol-2-yl)acetate
• CAS: 178755-48-1
• 化学式: C₁₁H₁₀N₂O₇S
• 分子量: 314.276
• InChiKey: ZOBDKXDZZXGWKJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  135
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (6-Nitro-1,1,3-trioxo-1,3-dihydro-1λ⁶-benzo[d]isothiazol-2-yl)-acetic acid ethyl ester 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 以91%的产率得到Ethyl 2-(6-amino-1,1,3-trioxo-1,2-benzothiazol-2-yl)acetate
  参考文献：
  名称：

  Da Settimo; Primofiore; La Motta, Il Farmaco, 1996, vol. 51, # 4, p. 261 - 267

  摘要：

  DOI：
• 作为产物：
  描述：

  2-甲基-5-硝基苯磺酰胺 在 chromium(VI) oxide 、 硫酸 、 碳酸氢钠 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 (6-Nitro-1,1,3-trioxo-1,3-dihydro-1λ⁶-benzo[d]isothiazol-2-yl)-acetic acid ethyl ester
  参考文献：
  名称：

  Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors

  摘要：

  Histone deacetylase (HDAC) is a clinically validated target for antitumor therapy. In order to increase HDAC inhibition and efficiency, we developed a novel series of saccharin hydroxamic acids as potent HDAC inhibitors. Among them, compounds 11e, 11m, 11p exhibited similar or better HDACs inhibitory activity compared with the approved drug SAHA. Further biological evaluation indicated that compound 11m had potent antiproliferative activities against MDA-MB-231 and PC-3. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.01.045

文献信息

• Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors
  作者：Leiqiang Han、Lei Wang、Xuben Hou、Huansheng Fu、Weiguo Song、Weiping Tang、Hao Fang

  DOI：10.1016/j.bmc.2014.01.045

  日期：2014.3

  Histone deacetylase (HDAC) is a clinically validated target for antitumor therapy. In order to increase HDAC inhibition and efficiency, we developed a novel series of saccharin hydroxamic acids as potent HDAC inhibitors. Among them, compounds 11e, 11m, 11p exhibited similar or better HDACs inhibitory activity compared with the approved drug SAHA. Further biological evaluation indicated that compound 11m had potent antiproliferative activities against MDA-MB-231 and PC-3. (C) 2014 Elsevier Ltd. All rights reserved.
• Da Settimo; Primofiore; La Motta, Il Farmaco, 1996, vol. 51, # 4, p. 261 - 267
  作者：Da Settimo、Primofiore、La Motta、Da Settimo、Simorini、Boldrini、Bianchini

  DOI：——

  日期：——